CSL Ltd
ASX:CSL
CSL Ltd
ASX:CSL
Price:
289 AUD
-0.17%
Market Closed
Updated:
Jun 8, 2024
CSL Ltd
Total Equity
|
CSL Ltd
Total Equity Peer Comparison
Comparables:
IMM
MSB
CUV
TLX
PYC
Competitive Total Equity Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
CSL Ltd
ASX:CSL
|
Total Equity
$17.2B
|
CAGR 3-Years
28%
|
CAGR 5-Years
29%
|
CAGR 10-Years
18%
|
|
|
Immutep Ltd
ASX:IMM
|
Total Equity
AU$115.6m
|
CAGR 3-Years
24%
|
CAGR 5-Years
28%
|
CAGR 10-Years
14%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Total Equity
$508.7m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Total Equity
AU$178.7m
|
CAGR 3-Years
32%
|
CAGR 5-Years
33%
|
CAGR 10-Years
32%
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Total Equity
AU$148.9m
|
CAGR 3-Years
24%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Total Equity
AU$29.9m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
26%
|
CAGR 10-Years
16%
|
See Also
What is CSL Ltd's Total Equity?
Total Equity
17.2B
USD
17.2B
USD
Based on the financial report for Dec 31, 2023, CSL Ltd's Total Equity amounts to 17.2B USD.
What is CSL Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
18%
18%
Over the last year, the Total Equity growth was 10%. The average annual Total Equity growth rates for CSL Ltd have been 28% over the past three years , 29% over the past five years , and 18% over the past ten years .
You don't have any saved screeners yet
